Integrated assessment of endocrine disrupting potential of four novel brominated flame retardants.

Abstract

Novel brominated flame retardants (NBFRs) have emerged as alternatives to the legacy BFRs due to BFRs' persistence, bioaccumulation and evidence of adverse health effects. The increasing production of NBFRs has led to the frequent detection in environmental media and even in organisms. Thus the potential health risks of these novel NBFRs need to be taken into account. Herein, the endocrine disrupting effects of the four NBFRs (α/β-TBCO, PBEB, EHTBB and BEHTBP) were evaluated by constructing an estrogen receptor (ERα), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR) mediated dual-luciferase reporter gene assays on the CHO cells, in combination with steroid experiments on the H295R cells and molecular docking. The results revealed that α/β-TBCO, PBEB and EHTBB induced anti-estrogenic activity at certain concentrations while none of the four NBFRs was agonistic to ERα. For reporter gene assay, only PBEB exhibited GR antagonistic effects. Notably, none of the four NBFRs possess neither agonistic nor antagonistic activity of MR. The molecular docking results were generally consistent with the reporter gene assay, which showed the different binding affinities between NBFRs and the receptors. For steroidogenesis, α/β-TBCO, PBEB, and EHTBB all upregulated genes encoding for steroid synthesis enzymes, including 17βHSD, CYP11B1 and CYP17. Altogether, the data clarified that NBFRs may pose risks of endocrine disruption.